heXem bio

HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells to extend healthy lifespan.

Health and bio

heXem bio raised $2M in a Seed round announced September 15, 2026, according to einpresswire.com. Investors in that round: Draper Associates, Boost VC, Happiness Capital, Korea Investment Partners, Seraphim Space, SOSV.

Founders and team

• SY
  Samet Yildirim Founder

  source: crunchbase.com
• DL
  Doug Lui Investor

  source: crunchbase.com

Raise history

1. September 15, 2026
   Seed · $2M
   DDraper Associates (lead), BBoost VC, HHappiness Capital, KKorea Investment Partners, SSeraphim Space, SSOSV
   Source: einpresswire.com

Investors

• BBoost VC
• DDraper Associates
• EEmerald Development Managers
• FFelipe Sierra
• HHappiness Capital
• JJoanne Kurtzberg
• KKorea Investment Partners
• SSeraphim Space
• SSOSV

Related bio health companies

• SSharp$328K · Oct 1, 2026
• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• VVytalYou$830K · Sep 30, 2026
• LLindera USSep 29, 2026
• OOrtet$500M · Sep 29, 2026
• AAptadir Therapeutics$45M · Sep 29, 2026
• GGoerSep 29, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/hexem-bio.